CFM
WVE icon

Catalyst Funds Management’s Wave Life Sciences WVE Stock Holding History

Catalyst Funds Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20
Closed -$123 – 1656
2024
Q1 		$123 Buy
+20
New +$100 ﹤0.01% 1082

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Catalyst Funds Management's WVE Position: Q2 2024 in Review

Catalyst Funds Management sold out of Wave Life Sciences (WVE) in Q2 2024, closing a stake of 20 shares — an estimated $123 sold.

Catalyst Funds Management first reported a position in WVE in Q1 2024 and held it in 1 quarter. The position peaked at $123 in Q1 2024. 144 funds tracked by Wall St. Rank hold WVE as of Q2 2024.

  • Catalyst Funds Management reported no remaining Wave Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 20 Wave Life Sciences shares in Q2 2024, an estimated $123.
  • Catalyst Funds Management first reported a position in Wave Life Sciences in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Wave Life Sciences position peaked at $123 in Q1 2024.
  • 144 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.